ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition
ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.
How this was made
The 30-second read
Why it matters
The key tradable update is the guidance increase for revenue, ROW organic growth, and non-GAAP diluted EPS range, supported by Q2 margin and EPS performance.
Market read
A same-day earnings and guidance update typically drives estimate revisions and near-term positioning, especially when revenue and ROW organic growth targets are raised.
What to watch
The filing emphasizes non-GAAP metrics; traders may scrutinize GAAP EPS softness (GAAP diluted EPS $1.35 vs non-GAAP $1.31) and free cash flow decline versus the prior year quarter.
Background
This is an SEC Form 8-K (Item 2.02) containing Illumina’s Q2 FY2026 results and updated FY2026 guidance.
Ticker impact
Illumina reported Q2 FY2026 revenue of $1.16B and raised FY2026 revenue guidance to $4.60-$4.64B and ROW organic growth to >5%.
Likely near-term positive bias as traders price higher 2026 revenue and EPS ranges; follow-through depends on whether NovaSeq X and multiomics demand sustains.
The filing is a primary disclosure (8-K with results and updated guidance) including specific numeric targets and margin/EPS outcomes, which typically drives immediate estimate revisions.
Market effects
Signals continued strength in sequencing and proteomics tooling demand, potentially supporting sentiment across genomics instrumentation and consumables peers.
ROW organic growth guidance (>5%) highlights ex-China momentum, which may shift regional demand expectations for sequencing spend.
China regulatory uncertainty remains a stated risk, but the guidance raise suggests management sees sufficient offset from other geographies.
Counterpoint
Raised guidance could still be vulnerable if China-related regulatory impacts or tariff/trade uncertainties materialize faster than management expects.
Key entities
- companyIllumina, Inc.
Nasdaq-listed genomics sequencing and proteomics platform provider reporting Q2 FY2026 results and raising FY2026 guidance.
- executiveJacob Thaysen
CEO quoted stating momentum and high NovaSeq X demand supported the guidance increase.
